- Home
- CTSO vs IKNA Comparison
CTSO vs IKNA Comparison
Compare CTSO & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- IKNA
- Stock Information
- Founded
- CTSO 1997
- IKNA 2016
- Country
- CTSO United States
- IKNA United States
- Employees
- CTSO N/A
- IKNA N/A
- Industry
- CTSO Medical/Dental Instruments
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- IKNA Health Care
- Exchange
- CTSO Nasdaq
- IKNA Nasdaq
- Market Cap
- CTSO 61.3M
- IKNA 64.7M
- IPO Year
- CTSO N/A
- IKNA 2021
- Fundamental
- Price
- CTSO $1.00
- IKNA $1.32
- Analyst Decision
- CTSO Strong Buy
- IKNA Buy
- Analyst Count
- CTSO 3
- IKNA 2
- Target Price
- CTSO $4.67
- IKNA $3.00
- AVG Volume (30 Days)
- CTSO 85.6K
- IKNA 84.9K
- Earning Date
- CTSO 05-08-2025
- IKNA 03-06-2025
- Dividend Yield
- CTSO N/A
- IKNA N/A
- EPS Growth
- CTSO N/A
- IKNA N/A
- EPS
- CTSO N/A
- IKNA N/A
- Revenue
- CTSO $37,739,531.00
- IKNA N/A
- Revenue This Year
- CTSO $9.20
- IKNA N/A
- Revenue Next Year
- CTSO $11.64
- IKNA N/A
- P/E Ratio
- CTSO N/A
- IKNA N/A
- Revenue Growth
- CTSO 1.80
- IKNA N/A
- 52 Week Low
- CTSO $0.70
- IKNA $1.22
- 52 Week High
- CTSO $1.61
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- CTSO 44.00
- IKNA 43.56
- Support Level
- CTSO $0.97
- IKNA $1.27
- Resistance Level
- CTSO $1.08
- IKNA $1.43
- Average True Range (ATR)
- CTSO 0.07
- IKNA 0.07
- MACD
- CTSO -0.01
- IKNA 0.00
- Stochastic Oscillator
- CTSO 17.53
- IKNA 37.21
Stock Price Comparison Chart: CTSO vs IKNA
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.